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Abstract
Background: Common carotid artery intima-media thickness (CIMT), as measured by ultrasound, has utility in
stratification of the accelerated cardiovascular risk seen in rheumatoid arthritis (RA); however, the technique has
limitations. Carotid magnetic resonance imaging (MRI) is emerging as a useful research tool in the general
population, but has yet to be applied in RA populations. Our objectives were to describe the utility of carotid artery
MRI (carotid-MRI) in patients with RA in comparison to healthy controls and to describe the association with RA
disease phenotype.
Methods: Sixty-four patients with RA and no history of cardiovascular (CV) disease/diabetes mellitus were assessed
for RA and CV profile, including homeostasis model assessment-estimated insulin resistance (HOMA-IR) and
N-terminal pro-brain natriuretic peptide (NT-proBNP). All underwent carotid-MRI (3 T), and were compared to 24
healthy controls. Univariable analysis (UVA) and multivariable linear regression models (MVA) were used to
determine associations between disease phenotype and carotid-MRI measures.
Results: There were no significant differences in carotid arterial wall measurements between patients with RA and
controls. Wall and luminal volume correlated with 10-year CV risk scores (adjusted as per 2017 European League
Against Rheumatism (EULAR) guidance); rho = 0.33 (p = 0.012) and rho = 0.35 (p = 0.008), respectively, for Joint
British Societies-2 risk score. In UVA, carotid-MRI volumetric measures predominantly were associated with
traditional CV risk factors including age, ever-smoking and HOMA-IR (p < 0.05). Lower body mass index was
associated with wall maximum thickness (r = − 0.25 p = 0.026). In MVA, age was independently associated with wall
volume (B 1.13 (95% CI 0.32, 1.93), p = 0.007) and luminal volume (B 3.69 (95% CI 0.55, 6.83, p = 0.022), and RA
disease duration was associated with luminal volume (B 3.88 (95% CI 0.80, 6.97), p = 0.015).
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Conclusions: This study demonstrates the utility of carotid-MRI in RA, reporting an association between three-
dimensional measures in particular and CV risk scores, individual traditional CV risk factors and RA disease duration.
Carotid-MRI in RA is a promising research tool in the investigation of CVD.
Keywords: Rheumatoid arthritis, Carotid MRI, Atherosclerosis
Introduction
Surrogate measures of cardiovascular disease (CVD) in
the general population have been applied to patients
with rheumatoid arthritis (RA) to investigate their accel-
erated cardiovascular (CV) risk. Common carotid artery
intima-media thickness (CIMT) is one of the best vali-
dated surrogate measures of CVD, predicting future CV
events in the general population [1]. It has also been
shown to be greater in patients with RA [2, 3], being as-
sociated with CV events [4], and demonstrating utility in
the stratification of CV risk in those with moderate
clinical CV risk scores [5].
CIMT is usually measured by ultrasound (US);
however, this method is operator dependent, and com-
parisons between studies are difficult due to varying
scanning protocols. Carotid magnetic resonance imaging
(carotid-MRI) provides alternative imaging of the carotid
artery, with MRI-measured mean wall thickness (MWT),
correlating well with US-measured CIMT [6–9]. There
is additional interest in MWT given it is the sum of the
vessel wall intima, media and also adventitia layer.
Evidence suggests the adventitia has an important role
in determining CV risk [8]. Specifically, in RA increased
expression of inflammatory cytokines in the aortic ad-
ventitia of patients with RA undergoing coronary artery
bypass grafts has been reported compared to patients
without RA [10]. Carotid-MRI measurements are associ-
ated with future CV events in the general population
[11], but have yet to be measured in RA populations.
This exploratory study aimed to demonstrate the novel
use of carotid-MRI in patients with established RA free
of known CVD and diabetes mellitus, in comparison to
healthy controls, and to describe the association between
carotid-MRI measures and RA disease phenotype, to
provide insight into the patient phenotype most at risk
of CVD.
Methods
Consecutive patients with RA attending rheumatology
clinics between January 2011 and September 2014 at the
Leeds Teaching Hospitals National Health Service
(NHS) Trust (LTHT) were considered for the IACON
(Inflammatory arthritis disease continuum longitudinal)
study; REC 09/H1307/98, approved by the Leeds West
ethics committee. Patients were eligible if they were be-
tween 18 and 80 years old, had had disease for 5 years
or more, met the 1987 American College of Rheumatol-
ogy (ACR) criteria [12] and had no history of CVD (car-
diac, peripheral or cerebral) or diabetes mellitus. Healthy
controls, with no history of RA or osteoarthritis that af-
fected their mobility, were mainly identified by asking
patients with RA to “bring a friend”. Carotid-MRI data
from two healthy controls consented into the study
“Assessment of myocardial perfusion by magnetic reson-
ance imaging: 3T optimization of acquisition and
analysis methods in patients with heart disease” (REC
10/H1307/103, Leeds West ethics committee) were also
utilised. Following written informed consent, study
participants were invited to undergo a cross-sectional
comprehensive CV clinical assessment, fasting blood
collection and carotid-MRI.
Clinical assessment
Demographic data, traditional CV risk factors and for
patients with RA, disease phenotype including 3-variable
(3v) Disease Activity Score in 28 joints (DAS28) based
on C-reactive protein (CRP) protein [13] and Health
Assessment Questionnaire Disease Index [14] were re-
corded on clinical evaluation. Fasting lipid profile and glu-
cose were measured, and rheumatoid factor, anti-cyclic
citrullinated peptide antibody, CRP and erythrocyte sedi-
mentation rate were measured in those with RA. Two
10-year cardiovascular risk scores were calculated, given
the pilot nature of this work; Framingham (commonly
used and therefore understood by a wide audience) and
Joint British Societies 2 (in line with our cardiology partner-
ship/network practice), and both were adjusted as per 2010
[15] and 2017 [34] European League Against Rheumatism
(EULAR) guidelines. Additional samples were processed
and stored for later measurement of NT-proBNP and
homeostasis model assessment-estimated insulin resistance
(HOMA-IR, fasting insulin (μU/ml) × fasting glucose (mg/
dl)/405) [16].
Carotid-MRI
Non-contrast carotid MRI was performed at 3.0 T
(Philips Achieva, Philips, Best, The Netherlands) using a
small 10-cm phased-array receiver coil (Philips dStream
Flex, Best, The Netherlands). Survey images were used
to locate the bifurcation of the common carotid artery
into the internal and external carotid artery. These im-
ages were used to plan perpendicular, non-breath-held,
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time-of-flight (ToF) proton density-weighted (PD), T1
and T2 weighted acquisitions of the common carotid ar-
tery (10 slices in total, 5 above and 5 below the carotid
bifurcation). Voxel sizes for each of these acquisitions
were as follows: ToF 0.89 × 0.89 × 3 mm, PD 0.7 × 0.7 ×
2 mm, T1 0.7 × 0.7 × 2 mm, T2 0.7 × 0.7 × 2 mm.
Using methodology similar to previously published
studies in the general population [17–19] as described
subsequently, a cardiology fellow (GF) reviewed and re-
ported the carotid-MR images blinded to all patient de-
tails and disease status using post-processing software
(QMASS MR 7.5, Medis, Leiden, The Netherlands). An
expert cardiovascular MRI-cardiologist (JPG) reviewed a
subset of images/contours to ensure all were assessed as
expected. A second junior then repeated contouring/
measurements for a subset of images to allow for calcu-
lation of inter-observer variability.
Cross-sectional T1-weighted images of the right
carotid artery were assessed in short-axis views. Slices 2,
4, 6 and 8 mm below the bifurcation of the common
carotid artery were identified, and the carotid artery
endothelial wall manually contoured on each slice. The
outer (adventitial) wall of the artery was also contoured
for each slice. Each cross-sectional image was then di-
vided into 6 segments, and the post-processing software
derived the minimum and maximum wall thickness,
along with MWT of all 24 segments of the carotid wall.
Figure 1 illustrates the images acquired and contours
drawn. The software then used the contours to calculate
the carotid wall mass (wall volume x the density of the
tissue (1.05 mg/ul) [20]) for all four slices, allowing
calculation of carotid wall volume. Total carotid wall
volume was normalised for vessel size (carotid wall
volume index) by calculating carotid wall volume/(ca-
rotid wall volume + luminal volume).
If the right carotid artery images were of poor quality
or did not provide enough slices, the left carotid artery
was used for measurement.
Statistical analysis
The statistical packages SPSS (IBM SPSS Statistics 22)
and Stata/IC 13.1 were used (the latter for calculating
robust standard errors). Following descriptive analysis,
the independent Student t test was used to determine
differences between patients with RA and controls.
Linear regression was used to determine differences
when adjusted for age, gender and CV risk factors
(defined as hypertension (either history of hyperten-
sion or on anti-hypertensive agent), dyslipidaemia
(either history of dyslipidaemia, on lipid-lowering
medication or total cholesterol/high-density lipopro-
tein cholesterol (TC/HDL-C) ratio > 6) and ever hav-
ing smoked). Non-normally distributed variables were
log-transformed prior to analysis.
Within the RA group, Spearman’s correlation was used
to measure associations between carotid-MRI measures
and 10-year CV risk scores, and Pearson’s correlation
and univariable linear regression analyses (UVA) were
used to measure associations between each of the base-
line variables and caroti- MRI measures, using
log-transformed values when appropriate. Any variables
reported in the literature as associated with carotid-MRI
measures or found to be strongly correlated in the pre-
liminary analyses (Pearson’s correlation coefficient > 0.3)
were then included in a multivariable linear regression
model. When the heteroskedasticity of regression model
residuals was not improved by logarithmic transform-
ation of the data, robust standard errors were employed.
Intra and inter-observer variability was tested
(between GF and LAB blinded to one another) for as-
sessment of carotid MWT to demonstrate an acceptable
coefficient of variance.
In the event of missing serology results the most
recent value preceding the visit was carried forward into
the data, excluding CRP due to its capacity to vary, or
lipid/glucose profile, as a fasting state could not be
verified.
Results
Study participant characteristics
Of 69 patients with RA and 25 healthy controls that
underwent a carotid-MRI scan, 64 with RA and 24 con-
trols had images available to analyse (using left carotid
images in 12 and 4 individuals, respectively); 4 data sets
were of poor quality and 2 were missing due to image
processing errors. Of the patients with RA, 60 patients
had data on carotid arterial wall volume measurements;
data were missing in 4 patients as the carotid artery
bifurcated too low to allow measurement up to 8 mm
below the bifurcation.
Table 1 outlines the demographic, CV risk profile and
soluble CV biomarkers, and Table 2 describes the RA
disease-specific features of those who had carotid artery
images available. The mean age (standard deviation) of
patients with RA was 59.6 (9.4) years, 70% were female
and 94% white. Median (interquartile range) disease dur-
ation was 17.3 (10.7, 25.7) years, 84% were seropositive
for rheumatoid factor (RF) or anti-citrullinated protein
antibodies (ACPA), 82% had erosive disease and 67%
were taking biological disease-modifying anti-rheumatic
drugs (DMARDs). Patients overall were in remission;
median (interquartile range) 3v DAS28 was 2.38 (1.15,
3.25). A significant proportion had CV risk factors, in-
cluding 33% with known hypertension. The control
group were younger (mean (standard deviation) age 51.8
(11.7) years) with fewer (54%) women and fewer CV risk
factors. There was little difference in glucose and lipid
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profile, HOMA-IR or NT-proBNP between patients with
RA and controls.
Carotid-MRI results
There were no significant differences between patients
with RA and controls in carotid arterial wall measure-
ments, including MWT, maximum wall thickness, wall
volume, luminal volume, wall volume index and wall
volume indexed/body surface area (BSA) (see Table 3).
Association with disease phenotype
In patients with RA, carotid wall volume and luminal
volume correlated well with 10-year CV risk scores
(adjusted as per 2010 [15] and 2017 [34] EULAR
guidelines). The 2010 adjustments appeared to perform
better; the carotid wall and luminal volume Spearman
correlation coefficients for the 2010 adjusted Joint
British Societies 2 risk scores were 0.37 (p = 0.005) and
0.43 (p = 0.001), respectively, compared to the 2017
adjusted Joint British Societies 2 risk scores (rho = 0.33
(p = 0.012) and rho = 0.35 (p = 0.008), respectively) (see
Table 4).
No variables (traditional CV risk factors or RA
disease-specific factors) were associated with carotid
MWT (see Additional file 1: Table S1). A history of
smoking and lower BMI correlated with higher max-
imum wall thickness (Pearson’s correlation coefficient
r = 0.25 p = 0.049, r = − 0.25 p = 0.026) (see Additional
file 1: Table S2); given r < 0.3, only age and gender
were added to the multivariable analysis model
(MVA) and no independent association was revealed.
In unadjusted analyses, increasing age (r = 0.35, p = 0.007)
and a history of smoking (r = 0.33, p = 0.010) were associ-
ated with carotid wall volume, although only age remained
independently associated in the MVA (B 1.13 (95% CI 0.32,
1.93), p = 0.007, R2 = 0.245 (see Table 5). Increasing age (r
= 0.37, p = 0.004), HOMA-IR (r = 0.30, p = 0.024) and
RA disease duration (r = 0.34, p = 0.007) were associated
Fig. 1 Cross-sectional T1-weighted images of the carotid artery in short-axis views. a Normal carotid artery, b carotid artery with plaque, c normal
carotid artery with contours, d carotid artery with plaque with contours. Red lines represent the endothelial wall and green lines represent the
outer (adventitial) wall of the carotid artery
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Table 1 Study participant characteristics
Variable Expressed as Patients with RA Controls
n = 64 n = 24
Demographics
Age, years mean, SD 59.6 (9.4) (range 31, 78) 51.8 (11.7) (range 35–80)
Female n (%) 45 (70.3) 13 (54.2)
Ethnicity n (%) 60 (94.0) white 21/22 (95.8) white
CV risk profile
PMH hypertension n (%) 22 (34.4) 1/21 (4.2)
PMH hypercholesterolaemia n (%) 16 (25.0) 1/21 (4.2)
Smoking status:
Never n (%) 28 (43.8) 11/21 (52.4)
Ex-smoker 28 (43.8) 8/21 (38.1)
Current 8 (12.5) 2/21 (9.5)
Alcohol intake, units/week median (IQR) 2 (0, 8) (n = 63) 1 (0, 6) (n = 21)
FHx premature CVDa n (%) 14 (21.9) 4/20 (16.7)
Five or more fruit/vegetables daily intake, days/week median (IQR) 5 (4, 7) (n = 63) 6 (4, 7) (n = 19)
Moderate exercise, mins/week median (IQR) 40 (0, 156) (n = 62) 60 (0, 240) (n = 20)
Number of current anti-hypertensives n (%) 8 (12.5) on 1 drug 1/21 (4.8) on 2 drugs
8 (12.5) on 2 drugs
1 (1.6) on 3 drugs
Current use of statin n (%) 11 (17.2) 1/21 (4.2)
BMI mean, SD 25.8 (3.3) 25.2 (3.4)
Waist/hip ratio mean, SD 0.84 (0.08) (n = 62) 0.82 (0.10) (n = 21)
Systolic BP, mmHg mean, SD 134 (20) 125 (14) (n = 23)
Diastolic BP, mmHg mean, SD 80 (12) 74 (10) (n = 23)
Fasting blood tests
Fasting glucose, mmol/L mean, SD 4.9 (1.0) (n = 60) 4.7 (0.5) (n = 19)
Fasting total cholesterol, mmol/L mean, SD 5.3 (1.1) (n = 63) 5.1 (1.0) (n = 19)
Fasting HDL-C, mmol/L mean, SD 1.6 (0.4) (n = 61) 1.6 (0.4) (n = 19)
Fasting LDL-C, mmol/L mean, SD 3.1 (1.0) (n = 61) 3.0 (0.9) (n = 19)
Fasting TC/HDL-C ratio mean, SD 3.4 (1.1) (n = 61) 3.3 (1.0) (n = 19)
Fasting triglycerides, mmol/Lb geometric mean 1.1 (n = 63) 1.0 (n = 19)
HOMA-IRb geometric mean 1.06 (n = 60)c 1.13 (n = 20)
NT-proBNP, pg/mlb geometric mean 53.3 (n = 60) 40.2 (n = 20)
Ten-year clinical risk scores
Framingham: median (IQR) 14.5 (6.3, 27.9)d 4.4 (1.3, 14.4) (n = 18)
14.6 (8.1, 29.1)e
Joint British Societies 2: median (IQR) 11.9 (4.9, 20.2)d 3.9 (0.8, 11.5) (n = 18)
12.0 (6.1, 22.2)e
BMI body mass index, BP blood pressure, CVD cardiovascular disease, FHx family history, HOMA-IR homeostasis model of assessment of insulin resistance, LDL-C
low-density lipoprotein cholesterol, NT-proBNP N-terminal pro-brain natriuretic peptide, PMH past medical history of, RA rheumatoid arthritis, TC/HDL-C total
cholesterol/high-density lipoprotein cholesterol ratio
aDefined as first-degree relative with a history of CVD when 60 years old or younger if female, and 55 years old or younger if relative
bVariables log transformed prior to analysis
cExcluding outlier: 1.01 (n = 59)
dAdjusted to 2010 European League Against Rheumatism (EULAR) guidelines [15]
eAdjusted to 2017 EULAR guidelines [34]
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with carotid luminal volume, although the association
with HOMA-IR was lost with the exclusion of the high
outlier. Age and RA disease duration remained inde-
pendently associated in the MVA (age, B 3.69 (95% CI
0.55, 6.83) p = 0.022, RA disease duration; B 3.88 (95%
CI 0.80, 6.97) p = 0.015, R2 = 0.257 (see Additional file
1: Table S3).
A history of previous joint surgery and increasing
HOMA-IR was associated with lower carotid wall
volume index (r = − 0.26 p = 0.043 and r = − 0.28 p = 0.035,
respectively), again the association with HOMA-IR
was lost with the exclusion of the outlier. Only age
and gender were included in the MVA and no
independent association was determined (see
Additional file 1: Table S4).
Intra-observer and inter-observer variability
Cardiology fellow GF re-analysed 10 carotid images. The
mean difference for intra-observer variability was 0.021
mm (95% CI − 0.012, 0.054) and the limits of agreement
were − 0.072 to 0.113 mm. The coefficient of variance
was 3.66%. The mean difference for inter-observer
assessments (between fellow GF and LAB, using 10
images) was 0.032 mm (95% CI − 0.075, 0.010) and the
limits of agreement were − 0.088 to 0.152 mm. The
coefficient of variance was 4.93%.
Table 2 Disease specific characteristics of patients with Rheumatoid Arthritis
RA phenotype Data expressed as Patients with RA, n = 68
Disease duration, years median (IQR) 17.3 (10.7, 25.7) (range 5.4, 43.4)
Early morning stiffness, mins median (IQR) 13 (0, 45) (n = 62)
History of orthopaedic joint surgery n (%) 19 (29.7)
Number of orthopaedic joint surgical episodes n (%) 9 (14.1) - 1 episode
3 (4.7) - 2 episodes
5 (7.8) - 3 episodes
2 (3.1) - 4 episodes
Current use of oral prednisolone n (%) 3 (4.7)
Current use of csDMARD n (%) 52 (81.3)
Number of csDMARDs currently taking n (%) 40 (62.5) taking 1
8 (12.5) taking 2
6 (9.4) taking 3
Number of previously tried csDMARDs median (IQR) 2 (1, 3) (range 0, 7)
Current use of biological DMARD n (%) 43 (67.2)
Current TNFI users 19 (29.7)
Current rituximab users 21 (32.8)
Current tocilizumab users 2 (3.1)
Current abatacept user 1 (1.6)
Number of treatment cycles in current RTX users median (IQR) 4 (3, 5.5) (range 2, 9)
Number of previously tried biological DMARDs median (IQR) 0 (0, 1)
Patient general health VAS median (IQR) 31 (16, 53) (n = 59)
TJC28 median (IQR) 2 (0, 6)
SJC28 median (IQR) 0 (0, 1)
HAQ-DI median (IQR) 1.50 (0.53, 2.00) (n = 60)
3-variable DAS28-CRP median (IQR) 2.38 (1.15, 3.25)
Erosions on hands/feet x-ray n (%) 50/61 (82)
CRP (mg/L) median (IQR) 0 (0, 8.3)
ESR (mm/h) median (IQR) 14 (6, 28) (n = 59)
RF positive (≥ 40 iu/ml) n (%) 44 (68.8)
ACPA positive (≥ 10 U/ml) n (%) 50/63 (79.4)
ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, csDMARDs conventional synthetic DMARDs, DAS28-CRP 28-joint disease activity score based on
CRP, DMARDs disease-modifying anti-rheumatic drugs, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, RF
rheumatoid factor, RTX rituximab, SJC swollen joint count, TJC tender joint count, VAS visual assessment score
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Discussion
This is the largest study to date using carotid-MRI to
describe carotid artery morphology in detail in compari-
son to healthy controls and the association with RA
disease phenotype. No significant differences were seen
in carotid wall measurements between those with RA
and healthy controls. However, carotid vessel wall and
luminal volumes correlated well with 10-year CV risk
scores, and were associated with traditional CV risk
factors, along with RA disease duration.
Carotid-MRI in RA has been reported in one recent
study. Skeoch et al. described late gadolinium-enhanced
carotid-MRI in 15 patients with RA and more than
2 mm of plaque on carotid ultrasound. They reported
more calcification in those with RA compared to five
controls despite similar plaque volume, remodelling
Table 5 Regression analysis of variables associated with carotid wall volume in patients with RA
Variable Carotid wall volume (ul)
Univariable analysis (n = 60, unless otherwise stated) Multivariable analysisb
R2 = 0.250, n = 60
Correlation coefficient B (95% CI) P value B (95% CI) P value
Agea 0.35 1.63 (0.47, 2.79) 0.007 1.13 (0.32, 1.93) 0.007
Male gendera 0.25 24.49 (0.01, 48.98) 0.050 15.99 (−10.62, 42.60) 0.234
Systolic blood pressure 0.13 0.28 (−0.29, 0.85) 0.329 – –
Ever smoked 0.33 29.71 (7.26, 52.16) 0.010 19.43 (−1.48, 40.34) 0.068
Body mass index −0.09 −1.16 (−4.66, 2.34) 0.508 – –
Waist/hip circumference 0.18 100.40 (−43.20, 244.001) (n = 58) 0.167 – –
TC/HDL-C −0.07 −2.92 (−14.74, 8.90) (n = 57) 0.622 – –
HOMA-IR 0.09 1.66 (−0.61, 3.93)b (n = 56)c 0.523 – –
NT-proBNP −0.09 −0.08 (− 0.33, 0.16) (n = 56) 0.499 – –
RA disease duration 0.31 1.36 (0.25, 2.46) 0.017 0.78 (−0.24, 1.79) 0.131
3-variable DAS28 −0.021 −0.75 (− 10.07, 8.57) 0.872 – –
ACPA 0077 8.58 (−21.004, 38.18) (n = 59) 0.564 – –
HAQ-DI 0.07 3.78 (− 11.98, 19.54) (n = 57) 0.633 – –
History of joint surgery −0.02 −1.76 (−27.45, 23.94) 0.892 – –
Current use of biological DMARD −0.02 −1.582 (−25.84, 23.79) 0.905 – –
ACPA anti-citrullinated peptide antibody, CI confidence intervals, CRP C-reactive protein, DAS28 28-joint disease activity score, DMARD disease-modifying
anti-rheumatic drug, HAQ-DI Health Assessment Questionnaire-Disability Index, HOMA-IR homeostasis model of assessment of insulin resistance, MWT mean wall
thickness, NT-proBNP N-terminal pro-brain natriuretic peptide, TC/HDL-C total cholesterol/high-density lipoprotein cholesterol ratio
aVariable entered into linear regression model as associated with carotid wall volume in the literature
bHeteroskedasticity of residuals therefore robust standard errors employed to compensate
cExcluding high outlier: correlation coefficient − 0.07 B (95% CI) − 3.82 (− 15.45, 7.82) p = 0.513
Table 4 The association between carotid wall variables in patients with RA and 10-year cardiovascular risk scores (adjusted as per
2010 and 2017 EULAR guidelines)
Variable Adjusted 10-year Framingham cardiovascular risk score Adjusted 10-year Joint British Societies 2 cardiovascular risk score
2010 EULAR guidelines 2017 EULAR guidelines 2010 EULAR guidelines 2017 EULAR guidelines
Rho 95% CI P value Rho 95% CI P value Rho 95% CI P value Rho 95% CI P value
Mean wall thickness 0.10 −0.16, 0.34 0.451 0.10 − 0.15, 0.35 0.426 0.09 −0.17, 0.33 0.514 0.09 −0.07, 0.33 0.517
Minimum wall thickness 0.12 −0.14, 0.36 0.368 0.13 −0.13, 0.37 0.335 0.13 −0.13, 0.37 0.322 0.13 −0.12, 0.37 0.309
Maximum wall thickness 0.06 −0.19, 0.31 0.622 0.05 −0.20, 0.30 0.684 0.04 −0.21, 0.29 0.734 0.03 −0.23, 0.28 0.848
Wall volumea 0.38 0.13, 0.58 0.004 0.34 0.09, 0.53 0.009 0.37 0.12, 0.58 0.005 0.33 0.08, 0.54 0.012
Luminal volumea 0.43 0.19, 0.62 0.001 0.35 0.10, 0.56 0.007 0.43 0.19, 0.62 0.001 0.35 0.10, 0.56 0.008
Wall volume indexeda − 0.22 −0.46, 0.04 0.094 −0.17 − 0.42, 0.09 0.198 − 0.23 −0.46, 0.04 0.088 −0.19 − 0.43, 0.08 0.167
Wall volume indexed/BSA −0.24 −0.47, 0.02 0.068 −0.21 − 0.45, 0.05 0.117 − 0.26 −0.48, 0.01 0.055 −0.23 − 0.46, 0.04 0.093
Number of observations = 61 unless otherwise stated. CI (confidence intervals) are of the correlation coefficient
RA rheumatoid arthritis, Rho Spearman correlation coefficient, EULAR European League Against Rheumatism, BSA body surface area
aNumber of observations = 57
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index and lipid-rich necrotic core measures. Addition-
ally, 12 of 13 of the patients with RA had evidence of
inflammation on (18)F-fluorodeoxyglucose positron
emission tomography scanning, correlating with highly
sensitive (hs)CRP, but not IL-6 levels or the DAS-28
[21]. Our study reported an association with traditional
CV risk factors and RA disease duration, but not CRP
or disease activity. However, overall our patients were
in remission (median 3-variable DAS28 = 2.38) and
those in the study by Skeoch et al. overall had mod-
erately active disease (mean DAS28 = 4.62), which
may explain this difference. Additionally, there are
recent ultrasound data demonstrating no progression
of CIMT over time in those in remission or with low
disease activity [22].
Carotid-MRI studies have previously demonstrated
an association with traditional CV risk factors in the
general population. The largest report from the “Ath-
erosclerosis risk in communities” study (n = 1670), re-
vealed carotid wall volume, thickness, and normalised
wall index were positively associated with lipids,
including total cholesterol, low-density lipoprotein
cholesterol (LDL-C), and apo-lipoprotein B [23]. Li et
al. reported that being male and being older were as-
sociated with MWT and maximum wall thickness in
196 study participants without CVD [24]. A smaller
study assessing those with obstructive sleep apnoea
(n = 42) found an association between maximum wall
thickness and waist/hip circumference, mean arterial
blood pressure, Framingham risk scores, HDL-C,
HOMA-IR, insulin and CRP [25].
The strongest associations with CV risk in our
study were observed in the three-dimensional (3-D)
volume measurements, which is an advantage of using
carotid-MRI over ultrasound. The 3-D outcome mea-
sures could provide a more accurate representation of
the carotid wall, given that they utilise more data in
their calculation. Carotid volumes are of particular
interest, as they could reflect carotid arterial wall
remodelling; in particular, positive remodelling (or
“compensatory enlargement”, seen in the initial stages
of atherosclerosis) where a compensatory increase in
lumen diameter occurs, together with an increase in
wall thickness, in an effort to reduce the development
of luminal stenosis. Positive remodelling has been
associated with hypertension [26], and also “softer
plaque”, i.e. less calcification, and greater plaque
instability [26, 27]. Interestingly, Van Sijl et al., using
ultrasound, determined that patients with RA (n = 96)
compared to controls (n = 274), despite having similar
CIMT values, had a larger vessel lumen diameter,
increased adventitia and greater wall stress and ten-
sion, after adjustment for CV risk factors [28], sug-
gestive of a positive remodelling process.
Limitations
There are many limitations associated with this study as
outlined below. No widely recognised protocol for
carotid-MRI reporting is currently available, and al-
though our methodology mirrored previously published
methods, this is an area in need of further study, includ-
ing concordance between right and left carotid artery
measurements. In addition, given the small differences
in carotid wall thickness, our inter-observer and
intra-observer variability limits of agreement are
relatively wide and any future larger study would need
to be appropriately powered to be meaningful. The vari-
ability in measurement may ultimately prove too wide
for carotid-MRI to be a valid outcome measure. This
cross-sectional study was also unable to quantify the
burden of inflammation to which patients with RA were
exposed over their disease duration. The cohort had
established severe disease (lengthy disease duration, high
proportion of seropositivity/erosions); therefore, al-
though they were in remission, we feel the total burden
of inflammation was likely significant as many had re-
quired multiple (including biological) disease-modifying
anti-rheumatic drugs and orthopaedic surgery. However,
the lack of association between carotid imaging mea-
surements and RA disease activity/inflammation may be
due to the smaller representation of those with high dis-
ease activity in our study population. The effect of acute
active RA disease compared to chronic active RA, and
those with previous high disease activity but now in re-
mission needs evaluating further with larger studies to
make any firm conclusions. We acknowledge that any
further study would also require matching for age/sex/
CV risk factors to have the greatest chance of detecting
any real difference, if present at all, between those with
RA and those without. Comparing carotid-MRI mea-
sures to US-measured CIMT would also help determine
the role/applicability of carotid-MRI in this field both as
a research tool and for clinical use in CV screening. Its
role in screening is especially important given the rela-
tive lack of access to, and greater cost/expertise required,
for carotid-MRI and the conflicting evidence supporting
inclusion of carotid artery structural measures in CV
risk scores in the general population [29, 30].
Future research agenda
In addition to the needs already discussed, larger
cross-sectional studies and prospective longitudinal
studies are required to validate the utility of carotid-MRI
in RA. The use of contrast to characterise carotid plaque
further, differentiating unstable from stable plaques,
lipid-rich necrotic cores from intra-plaque haemorrhage
[31], combined with positron emission tomography im-
aging [32] could potentially help provide information on
the pathophysiology of CVD in RA and on identifying
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those at risk of CVD. Our study also provides supportive
evidence for strategic management of modifiable trad-
itional CV risk factors in reducing CV morbidity and
mortality in RA; an important message given that the
management of such patients remains suboptimal [33].
Conclusions
This study has demonstrated the utility of carotid-MRI
in patients with RA, with initial results suggesting an
association with traditional CV risk factors, particularly
with 3-D carotid-MRI measures. In addition to reinfor-
cing the need to manage traditional CV risk factors ef-
fectively in RA, this study suggests a possible alternative
surrogate outcome measure for evaluating CV risk in
RA. Given the inclusion of the adventitia in carotid-MRI
measures, future studies should look to quantify any ad-
vantage over US-measured CIMT in the prediction of
future CVD, and investigate the utility of additional im-
aging techniques, such as positron emission tomography,
for clinical risk stratification and elucidating the under-
lying pathophysiology.
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